Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 60, Number 11, June 10, 2003
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okuda, D.
Right arrow Articles by Sivakumar, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okuda, D.
Right arrow Articles by Sivakumar, K.
Related Collections
Right arrow All Immunology
Right arrow Chronic inflammatory demyelinating polyneuropathy
Right arrow Muscle disease
Right arrow All Cerebrovascular disease/Stroke
Right arrow Infarction

Neurology 2003;60:1825-1826
© 2003 American Academy of Neurology
Brief Communications

Arterial thrombosis induced by IVIg and its treatment with tPA

Darin Okuda, MD, Murray Flaster, MD, James Frey, MD and Kumaraswamy Sivakumar, MD

From the Division of Neurology, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ.

Address correspondence and reprint requests to Dr. Sivakumar, Barrow Neurological Institute, Neuromuscular Research Center, 240 W. Thomas Rd., Phoenix, AZ 85013; e-mail: ksivakumar{at}chw.edu

IV immunoglobulin therapy can lead to vascular events through increased serum viscosity and possibly other mechanisms. The authors describe the successful use of tissue plasminogen activator in three of four patients who developed cerebral and peripheral arterial thrombosis after treatment with IV immunoglobulin.




This article has been cited by other articles:


Home page
 CJASNHome page
A. A. Vo, V. Cam, M. Toyoda, D. P. Puliyanda, M. Lukovsky, S. Bunnapradist, A. Peng, K. Yang, and S. C. Jordan
Safety and Adverse Events Profiles of Intravenous Gammaglobulin Products Used for Immunomodulation: A Single-Center Experience
Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 844 - 852.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
U Katz and Y Shoenfeld
Review: intravenous immunoglobulin therapy and thromboembolic complications
Lupus, October 1, 2005; 14(10): 802 - 808.
[Abstract] [PDF]

Home page
 Postgrad. Med. J.Home page
K H L Ng, A K L Wu, V C C Cheng, B S F Tang, C Y Chan, C Y Yung, S H Luk, T W Lee, L Chow, and K Y Yuen
Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome
Postgrad. Med. J., June 1, 2005; 81(956): e3 - e3.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
D J. McCabe, S Sumaria, and L A Wilson
Letter to the Editor
Lupus, May 1, 2005; 14(5): 409 - 410.
[PDF]

Home page
 Am J Health Syst PharmHome page
S. Shah and M. Vervan
Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis
Am. J. Health Syst. Pharm., April 1, 2005; 62(7): 720 - 725.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Dalakas and W. M. Clark
Strokes, thromboembolic events, and IVIg: Rare incidents blemish an excellent safety record
Neurology, June 10, 2003; 60(11): 1736 - 1737.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.